MedTrace Logo

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

NCT02134366 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-05-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.

Conditions

  • Epilepsia Partialis Continua
  • Kojewnikov's Epilepsy
  • Epilepsy

Interventions

DRUG

Clobazam

Comparison of AED use in Epilepsia Partialis Continua

DRUG

Clonazepam

Comparison of AED use in Epilepsia Partialis Continua

DRUG

Lorazepam

Comparison of AED use in Epilepsia Partialis Continua

Sponsors & Collaborators

  • Lundbeck LLC

    collaborator INDUSTRY

  • The Cooper Health System

    lead OTHER

Principal Investigators

  • Melissa Carran, MD · Cooper University Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02134366 on ClinicalTrials.gov